359 related articles for article (PubMed ID: 18474530)
1. Characterization of genome-wide p53-binding sites upon stress response.
Smeenk L; van Heeringen SJ; Koeppel M; van Driel MA; Bartels SJ; Akkers RC; Denissov S; Stunnenberg HG; Lohrum M
Nucleic Acids Res; 2008 Jun; 36(11):3639-54. PubMed ID: 18474530
[TBL] [Abstract][Full Text] [Related]
2. An integrative genomic approach identifies p73 and p63 as activators of miR-200 microRNA family transcription.
Knouf EC; Garg K; Arroyo JD; Correa Y; Sarkar D; Parkin RK; Wurz K; O'Briant KC; Godwin AK; Urban ND; Ruzzo WL; Gentleman R; Drescher CW; Swisher EM; Tewari M
Nucleic Acids Res; 2012 Jan; 40(2):499-510. PubMed ID: 21917857
[TBL] [Abstract][Full Text] [Related]
3. Genome-wide mapping indicates that p73 and p63 co-occupy target sites and have similar dna-binding profiles in vivo.
Yang A; Zhu Z; Kettenbach A; Kapranov P; McKeon F; Gingeras TR; Struhl K
PLoS One; 2010 Jul; 5(7):e11572. PubMed ID: 20644729
[TBL] [Abstract][Full Text] [Related]
4. p53FamTaG: a database resource of human p53, p63 and p73 direct target genes combining in silico prediction and microarray data.
Sbisà E; Catalano D; Grillo G; Licciulli F; Turi A; Liuni S; Pesole G; De Grassi A; Caratozzolo MF; D'Erchia AM; Navarro B; Tullo A; Saccone C; Gisel A
BMC Bioinformatics; 2007 Mar; 8 Suppl 1(Suppl 1):S20. PubMed ID: 17430565
[TBL] [Abstract][Full Text] [Related]
5. Identification of the interleukin 4 receptor alpha gene as a direct target for p73.
Sasaki Y; Mita H; Toyota M; Ishida S; Morimoto I; Yamashita T; Tanaka T; Imai K; Nakamura Y; Tokino T
Cancer Res; 2003 Dec; 63(23):8145-52. PubMed ID: 14678968
[TBL] [Abstract][Full Text] [Related]
6. A hidden Markov model for analyzing ChIP-chip experiments on genome tiling arrays and its application to p53 binding sequences.
Li W; Meyer CA; Liu XS
Bioinformatics; 2005 Jun; 21 Suppl 1():i274-82. PubMed ID: 15961467
[TBL] [Abstract][Full Text] [Related]
7. Wild-type p53 and p73 negatively regulate expression of proliferation related genes.
Scian MJ; Carchman EH; Mohanraj L; Stagliano KE; Anderson MA; Deb D; Crane BM; Kiyono T; Windle B; Deb SP; Deb S
Oncogene; 2008 Apr; 27(18):2583-93. PubMed ID: 17982488
[TBL] [Abstract][Full Text] [Related]
8. DNA modification with cisplatin affects sequence-specific DNA binding of p53 and p73 proteins in a target site-dependent manner.
Pivonková H; Pecinka P; Cesková P; Fojta M
FEBS J; 2006 Oct; 273(20):4693-706. PubMed ID: 16981908
[TBL] [Abstract][Full Text] [Related]
9. iASPP inhibits p53-independent apoptosis by inhibiting transcriptional activity of p63/p73 on promoters of proapoptotic genes.
Cai Y; Qiu S; Gao X; Gu SZ; Liu ZJ
Apoptosis; 2012 Aug; 17(8):777-83. PubMed ID: 22538442
[TBL] [Abstract][Full Text] [Related]
10. p63 consensus DNA-binding site: identification, analysis and application into a p63MH algorithm.
Perez CA; Ott J; Mays DJ; Pietenpol JA
Oncogene; 2007 Nov; 26(52):7363-70. PubMed ID: 17563751
[TBL] [Abstract][Full Text] [Related]
11. Differential regulation of MDR1 transcription by the p53 family members. Role of the DNA binding domain.
Johnson RA; Shepard EM; Scotto KW
J Biol Chem; 2005 Apr; 280(14):13213-9. PubMed ID: 15634666
[TBL] [Abstract][Full Text] [Related]
12. C-terminal diversity within the p53 family accounts for differences in DNA binding and transcriptional activity.
Sauer M; Bretz AC; Beinoraviciute-Kellner R; Beitzinger M; Burek C; Rosenwald A; Harms GS; Stiewe T
Nucleic Acids Res; 2008 Apr; 36(6):1900-12. PubMed ID: 18267967
[TBL] [Abstract][Full Text] [Related]
13. p73 and p63 sustain cellular growth by transcriptional activation of cell cycle progression genes.
Lefkimmiatis K; Caratozzolo MF; Merlo P; D'Erchia AM; Navarro B; Levrero M; Sbisa' E; Tullo A
Cancer Res; 2009 Nov; 69(22):8563-71. PubMed ID: 19861536
[TBL] [Abstract][Full Text] [Related]
14. Family members p53 and p73 act together in chromatin modification and direct repression of alpha-fetoprotein transcription.
Cui R; Nguyen TT; Taube JH; Stratton SA; Feuerman MH; Barton MC
J Biol Chem; 2005 Nov; 280(47):39152-60. PubMed ID: 16203738
[TBL] [Abstract][Full Text] [Related]
15. Physical interaction of tumour suppressor p53/p73 with CCAAT-binding transcription factor 2 (CTF2) and differential regulation of human high-mobility group 1 (HMG1) gene expression.
Uramoto H; Izumi H; Nagatani G; Ohmori H; Nagasue N; Ise T; Yoshida T; Yasumoto K; Kohno K
Biochem J; 2003 Apr; 371(Pt 2):301-10. PubMed ID: 12534345
[TBL] [Abstract][Full Text] [Related]
16. Control of p53-dependent transcription and enhancer activity by the p53 family member p63.
Karsli Uzunbas G; Ahmed F; Sammons MA
J Biol Chem; 2019 Jul; 294(27):10720-10736. PubMed ID: 31113863
[TBL] [Abstract][Full Text] [Related]
17. ChIP-on-chip analysis of in vivo mutant p53 binding to selected gene promoters.
Dell'Orso S; Fontemaggi G; Stambolsky P; Goeman F; Voellenkle C; Levrero M; Strano S; Rotter V; Oren M; Blandino G
OMICS; 2011 May; 15(5):305-12. PubMed ID: 21332394
[TBL] [Abstract][Full Text] [Related]
18. Identification of Daxx interacting with p73, one of the p53 family, and its regulation of p53 activity by competitive interaction with PML.
Kim EJ; Park JS; Um SJ
Nucleic Acids Res; 2003 Sep; 31(18):5356-67. PubMed ID: 12954772
[TBL] [Abstract][Full Text] [Related]
19. Glyoxalase II, a detoxifying enzyme of glycolysis byproduct methylglyoxal and a target of p63 and p73, is a pro-survival factor of the p53 family.
Xu Y; Chen X
J Biol Chem; 2006 Sep; 281(36):26702-13. PubMed ID: 16831876
[TBL] [Abstract][Full Text] [Related]
20. Expression of cyclin-dependent kinase subunit 1 (Cks1) is regulated during the cell cycle by a CDE/CHR tandem element and is downregulated by p53 but not by p63 or p73.
Rother K; Li YY; Tschöp K; Kirschner R; Müller GA; Mössner J; Engeland K
Cell Cycle; 2007 Apr; 6(7):853-62. PubMed ID: 17377499
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
